相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study
Meryam Maamar et al.
CURRENT MEDICAL RESEARCH AND OPINION (2022)
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial
Manuel Taboada et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients
Mohammed Abdel Monem Saeed et al.
EGYPTIAN JOURNAL OF INTERNAL MEDICINE (2022)
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial
Carlo Salvarani et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS
Francesco Salton et al.
JOURNAL OF CLINICAL MEDICINE (2022)
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022
Fiona P. Havers et al.
JAMA INTERNAL MEDICINE (2022)
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial
Marie W. Munch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases
Sorin Draghici et al.
BIOINFORMATICS (2021)
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial
Keivan Ranjbar et al.
BMC INFECTIOUS DISEASES (2021)
'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19
Swapna Mandal et al.
THORAX (2021)
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial
Jesus Villar et al.
LANCET RESPIRATORY MEDICINE (2020)
General Adaptation in Critical Illness: Glucocorticoid Receptor-alpha Master Regulator of Homeostatic Corrections
Gianfranco Umberto Meduri et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
A minimal common outcome measure set for COVID-19 clinical research
J. C. Marshall et al.
LANCET INFECTIOUS DISEASES (2020)
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Jonathan A. C. Sterne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A living WHO guideline on drugs for covid-19
Francois Lamontagne et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia
Francesco Salton et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS
Gianfranco Umberto Meduri et al.
INTENSIVE CARE MEDICINE (2020)
Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017
Djillali Annane et al.
CRITICAL CARE MEDICINE (2017)
Long-term prognosis in community-acquired pneumonia
Marcos I. Restrepo et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2013)
Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis
Sachin Yende et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Hydrocortisone infusion for severe community-acquired pneumonia - A preliminary randomized study
M Confalonieri et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)